信星集團(01170.HK)中期由盈轉虧3238萬港元 特息2港仙
格隆匯11月27日丨信星集團(01170.HK)公佈,截至2019年9月30日止6個月,公司收益5.41億港元,同比減少16%;毛利3759.2萬港元,同比減少50%;公司擁有人應占虧損3238萬港元,上年同期溢利3829.6萬港元;每股虧損4.7港仙,每股特別股息2港仙。
本期間內鞋履產品營業額因而按期減少16.0%至約541,000,000港元(2018年:約644,000,000港元),當中計入平均售價5.5%減幅及業務量(雙數)11.9%減幅。營業額下降亦由於若干新訂單下單延遲。儘管本期間整體平均售價較低,集團能為其新業務訂單實現更高的產品價值,反映銷售策略的成效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.